Innorab-20

Description

About Innorab-20 Capsule

Innorab-20 Capsule, manufactured by Innovative Pharma Lab Pvt. Ltd. and available in Nepal, contains the active ingredient Rabeprazole. This medication is a proton pump inhibitor (PPI). It works by suppressing gastric acid secretion through inhibiting the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cells.

What is Innorab-20 Capsule Used For?

Innorab-20 Capsule is prescribed for various conditions related to stomach acid production, including:

• Peptic ulcer disease
• H. pylori infection
• Gastro-oesophageal reflux disease (GERD), including in pediatric patients
• Zollinger-Ellison syndrome
• Oesophagitis (inflammation of the esophagus)
• Acid-related dyspepsia (indigestion)
• NSAID-associated ulceration (ulcers caused by pain relievers)
• Ulcers resistant to H2 receptor antagonists
• Gastrointestinal (GI) bleeding from stress
• Prophylaxis for acid aspiration syndrome during the induction of anesthesia

Dosage Information

The appropriate dosage of Innorab-20 Capsule varies depending on the condition being treated and the patient’s age and health. All oral doses should generally be taken once in the morning.

Adult Dosing (Oral)

• Gastro-oesophageal reflux disease (GERD):
  • Treatment: 20 mg once daily for 4-8 weeks.
  • Maintenance: 10 mg or 20 mg once daily.
• Zollinger-Ellison Syndrome:
  • Initial: 60 mg once in the morning.
  • Adjusted: Up to a maximum dose of 120 mg/day if needed. Daily doses greater than 100 mg should be given in 2 divided doses.
• Peptic Ulcer:
  • Duodenal ulcer: 20 mg once in the morning for 4-8 weeks.
  • Gastric ulcer: 20 mg once in the morning for 6-12 weeks.
• H. pylori Infection (1-week triple therapy):
  • 20 mg twice daily, combined with clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily, OR
  • 20 mg twice daily, combined with clarithromycin 250 mg twice daily and metronidazole 400 mg twice daily.
• Erosive Oesophagitis:
  • Treatment: 20 mg once daily for 4-8 weeks. May continue for another 8 weeks if healing is incomplete.
  • Maintenance: 10 mg or 20 mg once daily.
• Elderly Patients: No dosage adjustment is needed.
• Hepatic Impairment: No dosage adjustment is needed.

Child Dosing (Oral)

• Gastro-oesophageal reflux disease (GERD):
  • Children >12 years: 20 mg once in the morning for up to 8 weeks.

Renal Impairment

• No dosage adjustment is needed for patients with renal impairment.

Administration Guidelines

• Innorab-20 Capsule can be administered with or without meals.

Important Considerations

Contraindications

Rabeprazole is contraindicated in patients with known hypersensitivity to rabeprazole, other PPIs, or any component of the formulation.

Precautions

• Gastric malignancy should be ruled out before starting treatment.
• Use with caution in patients with severe hepatic impairment.
• Use with caution during pregnancy and lactation.
• Monitoring Parameters: Your doctor will monitor magnesium (Mg) levels prior to initiation and periodically during prolonged use.

Lactation

• It is unknown whether rabeprazole is distributed into breast milk; therefore, use caution if breastfeeding.

Interactions with Other Medications

Innorab-20 Capsule can interact with various other medications, potentially altering their effects:

• May decrease serum concentration: Ketoconazole, itraconazole, and clopidogrel.
• Increased risk: Hypomagnesaemia with diuretics and digoxin.
• May increase: Prothrombin time and INR of warfarin, plasma concentration of saquinavir and methotrexate.
• Decreased serum levels: Sucralfate.
• Potentially Fatal: May significantly decrease the plasma concentrations and pharmacological effects of rilpivirine and atazanavir.

Possible Side Effects

Common side effects (1-10% of patients) include:

• Headache (2-10%)
• Abdominal pain (4%)
• Diarrhea (2-5%)
• Flatulence (3%)
• Pain (3%)
• Pharyngitis (3%)
• Constipation (2%)

Less common side effects (<1%) that have been reported include:

• Agitation
• Agranulocytosis
• Alopecia
• Anemia
• Angioedema
• Chest pain
• Delirium
• Erythema
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Jaundice
• Leukocytosis
• Leukopenia
• Migraine
• Osteoporosis-related fracture
• Rhabdomyolysis
• Stevens-Johnson syndrome
• Sudden death
• Toxic epidermal necrolysis
• Abnormal taste

Important Note

This information about Innorab-20 Capsule is for general knowledge and is not intended as medical advice, diagnosis, or treatment. It should not replace the professional judgment of a healthcare provider. Always consult with your doctor or pharmacist for any health concerns or before making decisions about your medication.